References
- Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001;182:11-18S
- Bell TJ, Panchal SJ, Miaskowski C, et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med 2009;10:35-42
- De Schepper HU, Cremonini F, Park MI, Camilleri M. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil 2004;16:383-94
- Panchal SJ, Müller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract 2007;61:1181-7
- Kaufman PN, Krevsky B, Malmud LS, et al. Role of opiate receptors in the regulation of colonic transit. Gastroenterology 1988;94:1351-6
- Crabtree BL. Review of naltrexone, a long-acting opiate antagonist. Clin Pharm 1984;3:273-80
- Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2009;13:56-64
- Vondrackova D, Leyendecker P, Meissner W, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 2008;9:1144-54
- Simpson K, Leyendecker P, Hopp M, et al. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin 2008;24:3503-12
- Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129-38
- Leyendecker P, Hopp M, Bosse B, et al. Bowel function index – a new validated questionnaire for assessing opioid induced constipation. Proceedings of the IASP 12th World Congress on Pain 2008 Aug 17-22; Glasgow, Scotland
- Müller-Lissner S, Leyendecker P, Hopp M, et al. Oral prolonged release oxycodone/naloxone combination reduces opioid-induced constipation in patients with severe chronic pain. 2nd International Congress on Neuropathic Pain, Berlin Germany, 7-10 June 2007
- Wörz R, Frank M, Achenbach U. Retardiertes Oxycodon – eine Therapieoption bei starken neuropatischen Schmerzen. Zwei multizentrische Anwendungsbeobachtungen. MMW Fortschr Med 2003;145(Suppl 3):71-6
- Citron ML. Long-term administration of controlled-release oxycodone tablets for the treatment of cancer pain. Cancer Invest 1998;16:562-71
- Emrich O. Effektive Schmerzlinderung und Wiederherstellung der Beweglichkeit bei Schmerzen unterschiedlicher Genese. Ergebnisse einer Beobachtungsstudie mit Oxycodon. MMW 2007;148:157-61
- Hale, ME, Fleischmann R, Salzman R, et al. Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain. Clin J Pain 1999;15:179-83
- Nadstawek J, Leyendecker P, Hopp M, et al. Patient assessment of a novel therapeutic approach for the treatment of severe, chronic pain. Int J Clin Pract 2008;62:1159-67